SCHEMBL5308374

SCHEMBL5308374

CN1CCN(c2cc(F)cc3c2OC(C(=O)Nc2ccc(N4CCCC4=O)cc2)CC3)CC1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ HTR1B P28222 5/20 0.59
▸ KCNH2 Q12809 1/20 0.59
▸ NPC1 O15118 4/20 0.44
▸ RAB9A P51151 3/20 0.44
▸ SMN1; SMN2 Q16637 2/20 0.44
▸ ALDH1A1 P00352 1/20 0.44
▸ TP53 P04637 1/20 0.44
▸ GLA P06280 1/20 0.44
▸ PKM P14618 1/20 0.44
▸ HPGD P15428 1/20 0.40
▸ MAPT P10636 1/20 0.40
▸ KMT2A Q03164 3/20 0.40
▸ MEN1 O00255 1/20 0.40
▸ POLB P06746 1/20 0.40
▸ F10 P00742 2/20 0.39
▸ FPR2 P25090 1/20 0.39
▸ KDM4E B2RXH2 1/20 0.39
▸ RXFP1 Q9HBX9 1/20 0.39
▸ TSHR P16473 1/20 0.38
▸ KDM1A O60341 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5311900 0.90 HTR1B (0.57) HTR1BKCNH2SMN1; SMN2HPGDPOLB
SCHEMBL4250243 0.89 HTR1B (0.71) HTR1BKCNH2NPC1RAB9ASMN1; SMN2
SCHEMBL5308402 0.89 HTR1B (0.57) HTR1BKCNH2NPC1RAB9ASMN1; SMN2
SCHEMBL5308151 0.88 HTR1B (0.76) HTR1BKCNH2SMN1; SMN2ALDH1A1TP53
SCHEMBL14529930 0.88 HTR1B (0.57) HTR1BKCNH2NPC1RAB9ASMN1; SMN2
SCHEMBL5309254 0.87 HTR1B (0.60) HTR1BKCNH2NPC1RAB9ASMN1; SMN2
SCHEMBL5469032 0.87 HTR1B (0.54) HTR1BKCNH2SMN1; SMN2KMT2AMEN1
SCHEMBL5308451 0.86 HTR1B (0.78) HTR1BKCNH2NPC1RAB9ASMN1; SMN2
SCHEMBL5309051 0.86 HTR1B (0.58) HTR1BKCNH2NPC1RAB9ASMN1; SMN2
SCHEMBL14529770 0.85 HTR1B (0.66) HTR1BKCNH2NPC1RAB9ASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070135442-A1 Chroman compounds ASTRAZENECA AB (SE) 2007-06-14 — — US claimed
WO-2007053094-A1 CHROMAN COMPOUNDS AS 5 -HTlB ANTAGONISTS ASTRAZENECA AB (SE) 2007-05-10 — — WO claimed
US-20070135442-A1 Chroman compounds ASTRAZENECA AB (SE) 2007-06-14 — — US disclosed
US-20070135442-A1 Chroman compounds ASTRAZENECA AB (SE) 2007-06-14 — — US disclosed
US-20070135442-A1 Chroman compounds ASTRAZENECA AB (SE) 2007-06-14 — — US disclosed
WO-2007053094-A1 CHROMAN COMPOUNDS AS 5 -HTlB ANTAGONISTS ASTRAZENECA AB (SE) 2007-05-10 — — WO disclosed
WO-2007053094-A1 CHROMAN COMPOUNDS AS 5 -HTlB ANTAGONISTS ASTRAZENECA AB (SE) 2007-05-10 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070135442-A1 Chroman compounds CYP3A43, CYP2C9, CYP2C8 HTR1B 592/4885KCNH2 1018/4885NPC1 773/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback